转自：北京日报客户端 螺旋聚合物和上海中心大厦结构示意图。资 料图片 近期，中国与荷兰科学家合作完成的一项新成果发表在《自然·化学》杂志上：研究团队首次在实验室 中成功合成出具有明确内外双层螺旋结构的动态高分子。这一分子结构的设计灵感源自上海中心大厦的 独特建筑形态，分子高度仅几十纳米、直径仅2纳米，相当于将632米高的摩天大楼缩小至约10亿分之 一，是人类头发丝的800万分之一。实验表明，该材料展现出类似天然蛋白质的动态行为，可随温度变 化伸缩、在特定条件下完全解旋，并最终降解为人体可吸收的小分子，无残留风险，这为仿生智能材料 的研发开辟了新路径。 从建筑奇观到功能材料 该研究由华东理工大学费林加诺贝尔奖科学家联合研究中心完成。2019年，研究团队在参观上海中心大 厦时受到启发。该大厦于2016年建成，是目前中国第一高楼、世界第三高楼，以多项创新技术在超高层 建筑史上具有里程碑意义。研究团队特别注意到，其独特的内外双层螺旋外观不仅赋予建筑独特的空气 动力学稳定性，也令人联想到生命体系中的螺旋结构，如DNA和某些蛋白质。由此，研究团队提出一 个科学设想：能否在非生物体系中，通过化学合成手段构建具有类似几何特征 ...

该研究由华东理工大学费林加诺贝尔奖科学家联合研究中心完成。2019年，研究团队在参观上海中心大 厦时受到启发。该大厦于2016年建成，是目前中国第一高楼、世界第三高楼，以多项创新技术在超高层 建筑史上具有里程碑意义。研究团队特别注意到，其独特的内外双层螺旋外观不仅赋予建筑独特的空气 动力学稳定性，也令人联想到生命体系中的螺旋结构，如DNA和某些蛋白质。由此，研究团队提出一 个科学设想：能否在非生物体系中，通过化学合成手段构建具有类似几何特征和动态功能的人工高分 子？ 生物体内的螺旋高分子承担着信息存储、结构支撑或催化等关键功能，其精密构型被认为是"生命密 码"的物理载体。然而，数十年来，化学家虽然能合成出螺旋结构高分子，但往往基于难降解、难回收 的刚性骨架，不具备天然螺旋高分子一样的动态功能。 此次研究团队从最基础的小分子出发，尝试将氨基酸、二硫键等天然的、与生物相容的"分子积木"，通 过动态可逆的化学键连接起来，构筑出稳定的螺旋构象。不过，早期设计的分子仅靠氢键等弱相互作用 维持螺旋，一旦受热或环境变化，结构便迅速"坍塌"。 螺旋聚合物和上海中心大厦结构示意图。 资料图片 近期，中国与荷兰科学家合作完成的一 ...

Emerging Fields - The release of five national standards related to cybersecurity technology aims to strengthen the national cybersecurity defense and promote the healthy development of the digital economy [1] - Seven national standards in information technology will ensure the interoperability and security of information systems through unified technical application specifications [1] - Three national standards for social experiments in artificial intelligence support the healthy and orderly development of an intelligent society [2] - Seven national standards in nanotechnology will assist in the unification of relevant technical characterization and testing specifications [2] Transportation and Environmental Protection - A total of 44 national standards have been released for automotive steering systems, vehicle brake fluids, railway construction machinery, rail transit vehicles, shore power for ships, containers, and aerospace components, contributing to the construction of a strong transportation nation [2] - Ten energy-saving and environmental protection standards have been published for industrial boilers, meat processing, food processing, alcoholic beverages, and lead-zinc, aiding in the fight against pollution [2] Safety Production - National standards for assessing the risk of combustible dust explosions and guidelines for the construction and operation of gas protection stations in chemical parks have been released to further regulate the management of hazardous chemicals and enhance safety levels in chemical parks [2] - Five national standards for emergency management, including guidelines for evaluating emergency drills and constructing emergency plans, aim to improve emergency response capabilities [2] - Eleven mandatory national standards for fire trucks have been published to ensure technological advancement in fire truck products and effectively enhance the operational capabilities of firef and rescue teams [2] Public Services - Three national standards for educational service management and guidelines for standardized educational course construction in logistics, elderly care, automation, and the Internet of Things have been released to lay the foundation for cultivating compound talents and promoting the integration of education and industry [3] - Guidelines for the usability of home health care products and related services have been published to support the construction of an elderly-friendly society [3] - Four national standards related to asset management digital maturity and cultural digital asset value assessment aim to continuously improve the digitalization level of asset management and enhance the transparency and security of digital asset transactions [3] Quality of Life - National standards for smart textiles have been released to guide the standardized development of intelligent textiles [3] - A national standard for biodegradable plastic shopping bags has been published to promote resource recycling [3] - National standards for testing methods related to formaldehyde content in leather and fur, as well as short-chain chlorinated paraffins, have been established to improve the detection of harmful substance limits [3] - Eight national standards for surgical implants and sterilization of medical products have been released to enhance the quality and safety of medical devices [3]

Core Insights - The article discusses the annual venture capital conference in Shenzhen, focusing on the theme of "missed opportunities and heavy investments" in the context of investment strategies and industry shifts in China [2][3]. Group 1: Investment Institutions Overview - Tang Capital, founded in 2019, focuses on hard technology, particularly in electronic information, advanced manufacturing, and new materials, managing over 3 billion [3]. - Huakong Fund, established in 2007, has over 10 billion under management, emphasizing hard technology sectors such as advanced manufacturing and AI [4]. - Huaying Capital, founded in 2008, has invested in over 280 companies, with over 50% of investments related to AI [4]. - Guozhong Capital, established in 2015, manages 16 billion across multiple funds, focusing on supporting small and medium-sized enterprises [5]. - Lenovo Star, since 2008, has invested in over 400 companies, primarily in technology and healthcare [6]. - Linghang New Frontier, founded in 2019, manages approximately 2.8 billion, focusing on smart technology and biomedical sectors [7]. - Tiantang Silicon Valley, established in 2000, has invested in over 230 projects, with over 50% achieving exits, focusing on technology and healthcare [8]. Group 2: Investment Strategies and Shifts - Investment strategies have evolved due to industry cycles, with institutions adjusting their focus based on market conditions and technological advancements [9][16]. - Huaying Capital's investment methodology adapts to different stages of technology development, focusing on disruptive technologies and market leadership [12]. - Institutions like Tang Capital and Huakong Fund emphasize AI and advanced technologies as key future investment areas, reflecting a shift towards more innovative sectors [29][30]. - Guozhong Capital aligns its investment strategy with national development plans, focusing on emerging industries as outlined in the "14th Five-Year Plan" [19]. Group 3: Missed Opportunities and Lessons Learned - Many institutions shared experiences of missed opportunities in sectors like quantum computing and commercial aerospace, highlighting the importance of timely decision-making [25][27]. - The article emphasizes the need for continuous learning and adaptation in investment strategies to avoid missing out on emerging trends [26][28]. - Institutions reflect on past mistakes, such as underestimating the potential of the solar energy sector, which has since become a leading industry [26]. Group 4: Future Focus Areas - Future investment focus areas include AI, embodied intelligence, and commercial aerospace, with expectations for significant growth in these sectors [29][30]. - Institutions are also looking at advanced materials and renewable energy as key investment opportunities over the next five years [32][33].

市场监管总局批准发布一批重要国家标准 涉及新兴领域等方面 中新网12月9日电 据国家市场监管总局网站消息，近日，市场监管总局(国家标准委)批准发布一批重要 国家标准，涉及新兴领域、交通运输和环境保护、安全生产、公共服务等方面，本批标准发布后将在提 升人民群众生活品质、保障生命财产安全等方面发挥重要作用。 在新兴领域方面，发布网络安全技术等5项国家标准，支撑筑牢国家网络安全防线、推动数字经济健康 发展。发布信息技术等7项国家标准，通过统一技术应用规范，保障信息系统互联互通与安全可靠。发 布人工智能社会实验等3项国家标准，支撑智能社会健康有序发展。发布纳米技术等7项国家标准，助力 统一相关技术表征与测试规范。 在交通运输和环境保护方面，发布汽车转向系、机动车辆制动液、铁路施工机械、轨道交通车辆、船舶 岸电、集装箱、宇航元器件等44项国家标准，助力交通强国建设。发布工业锅炉经济运行、肉类加工、 食品加工、酒类、铅锌等10项节能环保标准，助力打赢污染防治攻坚战。 广告等商务合作，请点击这里 本文为转载内容，授权事宜请联系原著作权人 中新经纬版权所有，未经书面授权，任何单位及个人不得转载、摘编或以其它方式使用。 关注中 ...

Overview - The global number of end-stage heart failure patients is large, and heart transplantation is limited by donor scarcity. The success rate of patients receiving transplant surgery is very low. Implantable artificial hearts serve as an important alternative to heart transplantation, providing transitional treatment for patients awaiting transplant and long-term treatment for those unsuitable for transplantation. In 2024, the global implantation volume of implantable artificial hearts is expected to reach 7,538 units, a year-on-year increase of 33.84%, with a market size of $1.2 billion, also up by 33.33% [1][8]. Industry Barriers to Entry - The research and development of artificial hearts involve a multidisciplinary approach, requiring expertise in mechatronics, mechanical design, fluid mechanics, biomechanics, materials science, and clinical medicine. Currently, only a few medical device companies globally have the capability to engage in this industry, making it difficult for new entrants to gain a competitive advantage in the short term. The production of these devices requires high-quality control and complex manufacturing processes, necessitating long-term practical experience and technological breakthroughs [2][4]. Relevant Policies - The medical device industry, including implantable artificial hearts, is a strategic emerging industry in China, receiving significant attention from the government. Various policies have been issued to regulate the market, ensure product quality, and safeguard patient safety, creating a favorable environment for the development of the implantable artificial heart industry [4][5]. Industry Chain - The upstream of the implantable artificial heart industry includes suppliers of metals like titanium and stainless steel, polymer materials like polyurethane and polyethylene, core components like magnetic suspension motors and precision bearings, as well as external controllers and batteries. The midstream involves the research and production of implantable artificial hearts, while the downstream consists of healthcare institutions and heart failure patients, with the core consumer group being end-stage heart failure patients [5][6]. Current Development - The number of heart failure patients is increasing globally, driven by aging populations and the prevalence of chronic diseases. In 2024, the global number of heart failure patients is projected to reach 63 million, with end-stage heart failure patients numbering 6.1 million. In China, the number of heart failure patients is expected to reach 15.4 million, with 1.6 million in the end-stage category. This rising patient population is driving demand for implantable artificial hearts [7][8]. Competitive Landscape - The implantable artificial heart market has high technical barriers, with overseas companies having a head start. Abbott's HeartMate3 holds a significant market share globally. In China, five models of implantable artificial hearts have been launched, with Shenzhen Core Medical Technology Co., Ltd.'s Corheart®6 showing notable technological advantages. As of early 2025, Core Medical's Corheart6 accounted for 52.86% of the market share in terms of implantation volume [9][10]. Representative Domestic Companies - Shenzhen Core Medical Technology Co., Ltd. focuses on innovative artificial heart products and has developed five implantable and six interventional heart products. In 2024, the revenue from its left ventricular assist system reached approximately 93.69 million yuan, a year-on-year increase of 466.08% [10][11]. - Suzhou Tongxin Medical Technology Co., Ltd. has developed the first fully magnetic suspension left ventricular assist device in China, which has received regulatory approval. This product features several innovative technologies, marking a significant advancement in the domestic artificial heart field [11][12]. Future Development Trends - The industry is expected to see continued optimization of magnetic suspension technology, leading to improved stability and longevity of devices. There will be a trend towards smaller and lighter products to reduce surgical trauma and enhance post-operative convenience. Additionally, the integration of artificial intelligence and IoT technologies is anticipated to improve remote monitoring and management of patients post-surgery. The application of advanced materials may also reduce infection and rejection risks, expanding the use of implantable artificial hearts beyond adult end-stage heart failure patients to more specific scenarios [12].

Core Insights - The "China Pet Industry Scientific Research Innovation and Achievement Transformation Conference" was successfully held in Guangzhou, marking a significant step towards high-quality and sustainable development in the pet industry [1][7] - The conference emphasized the theme of "innovation-driven, cooperative win-win," focusing on the integration of technology and industry [3] Group 1: Conference Highlights - The conference featured a pet technology experience zone showcasing innovative technologies such as antibacterial plastics, nano-fiber testing reagents, and long-lasting fragrance systems [3] - A strategic cooperation agreement was signed between CPCRA and NAMI to establish the "Greater Bay Area Pet Health Technology Innovation Center," aiming to integrate resources and focus on the research and transformation of nanotechnology in the pet sector [3] - The "Expert Think Tank" of the Guangdong Pet Industry Association was launched, appointing ten cross-disciplinary experts to support the standardized development of the industry [3] Group 2: Industry Discussions - NAMI's expert team delivered five thematic presentations on the application prospects of nanotechnology in pet health, environment, and diagnostics [5] - A roundtable discussion focused on the integration of pet fresh food and health technology, where multiple experts explored technical challenges, market pain points, and cross-industry collaboration paths [5] - The conference facilitated frequent interactions among attendees, highlighting the industry's urgent demand for collaborative innovation and strong momentum for market applications and investment opportunities [5]

Market Overview - US stock market experienced a rebound with the Dow Jones up by 1.08%, S&P 500 up by 0.98%, and Nasdaq up by 0.88%, providing a glimmer of hope after three weeks of declines [1] - Chinese concept stocks also saw an increase, with the index rising by 0.84%, indicating a positive sentiment among investors [7] A-share Market Performance - A-share market faced a significant drop, with the Shanghai Composite Index falling by 2.45%, and the ChiNext Index dropping over 4%, marking the largest decline in nearly six months [10] - Over 5,000 stocks in the A-share market declined, with more than 100 stocks hitting the daily limit down [10] Sector Performance - Notable sectors included gene editing, which surged by 10.50%, and nanotechnology, which rose by 8.13%, showcasing strong performance in specific areas [4][5] - Despite the overall market downturn, certain sectors like the shipbuilding sector and video content related to artificial intelligence showed resilience, indicating selective investment opportunities [17] Investor Sentiment - The market sentiment is characterized by fear and pessimism, with many retail investors caught off guard by the sudden drop [10] - However, historical patterns suggest that extreme sell-offs often lead to technical rebounds, creating potential for recovery [15] Future Outlook - Analysts predict a high probability of a short-term rebound, with the key focus on whether the market can maintain momentum and attract new capital [20] - The performance of Northbound capital will be a crucial indicator for market confidence moving forward [20] - The biotechnology and semiconductor sectors are highlighted as potential areas for investment, especially if market sentiment improves [21]

Core Insights - The article highlights that China is surpassing the United States in scientific research output and certain cutting-edge fields, indicating a potential end to the dominance of Silicon Valley and top U.S. universities in shaping the future of science [1] Research Output Comparison - In 2024, Chinese researchers published 1.1 million papers compared to 880,000 from the U.S., showing an expanding gap in research output [1] - In the medical field, China's share of published papers rose from 40% in 2023 to over 50% in 2024 [1] - China leads in energy research, accounting for approximately 35% of global publications in this area [1] Quality of Research - China is not only leading in quantity but also in high-quality research output, as indicated by patent filings and other metrics [1] Influence on Other Countries - China's rise in scientific research is becoming a model for other countries, particularly Vietnam, which aims to significantly increase R&D investment to replicate China's past successes [1] Vietnam's R&D Plans - Vietnam plans to establish five tech companies valued at $1 billion by 2025 and ten by 2030, with R&D investment expected to reach 1.5% of GDP by 2025 [3] - However, as of 2023, Vietnam's R&D investment was only 0.43% of GDP, indicating challenges in innovation [3] Emerging Technologies - China is making significant contributions in key future technology areas, including green nitrogen fixation, next-generation nuclear energy, and generative watermarking technology [5] - The World Economic Forum's collaboration with the journal "Frontiers" highlights these technologies as critical for the next five to ten years [5] Publishing Infrastructure - The increasing number of Chinese universities and publishers launching their own journals and platforms is seen as a natural evolution to support the growing research output [5] - The journal "Frontiers" is adopting AI tools to enhance efficiency in scientific publishing, predicting a fundamental transformation in the field within five years [5]

Core Viewpoint - Inorganic antimicrobial agents, including silver ions and metal oxide photocatalysts, are gaining traction due to their broad-spectrum antibacterial properties, low toxicity, and heat resistance, especially with advancements in nanotechnology enhancing their effectiveness compared to traditional agents [1][4]. Market Overview - The inorganic antimicrobial agent market in China reached USD 92.30 million in 2024 and is projected to grow to USD 153.67 million by 2031, with a compound annual growth rate (CAGR) of 6.50% from 2025 to 2031 [4]. - The market volume is expected to increase from 4,287.0 tons in 2024 to 6,403.0 tons by 2031, reflecting a CAGR of 5.65% during the same period [4]. Product Types and Applications - The market is segmented into various product types, including silver-based, copper-based, and zinc-based antimicrobial agents, with silver-based agents holding a market share of 60.75% in 2024 [6]. - Key application areas include plastics and rubber, coatings, textiles, furniture and appliances, construction materials, medical applications, footwear materials, and glass, with plastics and rubber accounting for 19.48% of the market share in 2024 [6]. Supply Chain Analysis - The upstream supply chain involves sourcing raw materials such as metal ions (silver, zinc, copper) and inorganic fillers (zirconium phosphate, titanium dioxide, silica, zeolite), which directly impact the performance of antimicrobial agents [9]. - The midstream focuses on the research and development of new antimicrobial products, with collaboration between research institutions and companies to innovate and improve product efficacy [10]. - The downstream sector encompasses the application and marketing of antimicrobial agents across various industries, enhancing product competitiveness through added antimicrobial properties [11]. Market Drivers - Technological advancements, particularly in nanotechnology and artificial intelligence, are facilitating the development of new antimicrobial agents, improving efficacy and reducing resistance [12]. - Increasing public health concerns regarding bacterial infections and antibiotic resistance are driving demand for effective antimicrobial solutions [12]. - The expansion of applications in various industries, including healthcare, coatings, textiles, and food packaging, is further propelling market growth [12]. Market Restraints - Limitations in technology and product performance, such as reduced antimicrobial activity in extreme pH or high-temperature environments, pose challenges [14]. - Cost pressures from fluctuating raw material prices and high production costs for advanced formulations hinder market penetration [18]. - High application concentration in specific sectors limits broader adoption in higher-value areas like food packaging and medical devices [19]. Regulatory Environment - Stringent regulations on synthetic preservatives and a preference for natural, biodegradable products are influencing market dynamics [13]. - Variability in regulations across regions regarding antimicrobial material standards necessitates compliance for export-oriented companies [21]. Key Policies - The "Heavy Metal Environmental Safety Hazard Investigation and Rectification Action Plan (2025-2030)" aims to enhance heavy metal pollution control, impacting the production and use of inorganic antimicrobial agents [24]. - New standards for antimicrobial performance testing and safety requirements are being implemented to ensure product efficacy and consumer safety [24]. Industry Competitors - Major players in the Chinese inorganic antimicrobial agent market include Toagosei, Ishizuka, Shanghai Langyi Functional Materials, BASF, and Microban, with the top five companies holding a market share of 64.89% in 2024 [6][27].